Assessing the cost-effectiveness of first line treatment options using a patient-level simulation model designed to integrate the impact of adherence and non-aids related morbidities on long-term cost-effectiveness.
Customer: Gilead Sciences
Main Goal: Assessing the cost-effectiveness of first line treatment options using a patient-level simulation model
Main Result: poster presentation at BREACH 2017
Few models have concurrently integrated the impact of treatment adherence on HIV infection outcomes and the impact of HIV and its treatment on non-AIDS related morbidities (NARMs). These elements may have an important influence on long-term cost-effectiveness.
We adapted a previously developed model to the Belgian context in order to compare the cost-effectiveness of first-line treatment of a TAF/FTC backbonebased single tablet therapy (Genvoya) to commonly used non-TAF/FTC backbone single tablet regimens (EVG/TDF/FTC - Stribild, DTG/ABC/3TG -Triumeq, RPV/TDF/FTC - Eviplera) in treatment naïve patients newly diagnosed with HIV starting ART.
